Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-HAAH monoclonal antibodies - Sensei Biotherapeutics

Drug Profile

Research programme: anti-HAAH monoclonal antibodies - Sensei Biotherapeutics

Alternative Names: PAN 22; PAN-355; PAN-622

Latest Information Update: 17 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Goodwin Biotechnology; Massachusetts Institute of Technology; Sensei Biotherapeutics
  • Class Monoclonal antibodies; Radiopharmaceutical diagnostics
  • Mechanism of Action Aspartic acid 2-oxoglutarate-dependent dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer
  • No development reported Liver cancer

Most Recent Events

  • 16 May 2018 Panacea Pharmaceuticals is now called Sensei Biotherapeutics
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top